{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:36:06Z","timestamp":1777448166154,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["The American Surgeon\u2122"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High output is a common cause for readmission after new ileostomy creation. The loss of sodium leads to compensatory activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are first-line therapy for hypertension in the United States. We hypothesized that concurrent use of ACEI\/ARB increases the risk of readmission following new ileostomy creation due to the loss of this compensatory mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients undergoing ileostomy creation between 2009-2022 at an integrated managed health care system were included in this retrospective study. Primary outcomes were hospital readmission and ED visit within 30-days. Additional variables included ACEI\/ARB use, ileostomy type, Charlson Comorbidity Index, additional antihypertensives at discharge (furosemide, hydrochlorothiazide, spironolactone, amlodipine, nifedipine, and diltiazem), and readmission diagnosis. Descriptive and advanced statistical analysis was completed with SPSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 540 patients, 41.9% were readmitted or visited an ED within 30 days. There was no difference in readmission or ED visit based on age, gender, or ileostomy type. Patients discharged with ACEI\/ARB (37.4% vs 25.5%,\n                      <jats:italic>P<\/jats:italic>\n                      = .005) and additional antihypertensives (37.2% vs 17.3%,\n                      <jats:italic>P<\/jats:italic>\n                      = .006) were at a higher risk for readmission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inhibition of RAAS is associated with increased risk for hospital readmission. In patients with hypertension undergoing ileostomy creation, individualized care plans are needed with earlier antimotility agent use or intravenous rehydration plans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00031348241307396","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T09:56:23Z","timestamp":1733824583000},"page":"556-560","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Angiotensin-Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) Use are Associated With Increased Readmission After Ileostomy Creation"],"prefix":"10.1177","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1835-1218","authenticated-orcid":false,"given":"Connie Y.","family":"Gan","sequence":"first","affiliation":[{"name":"Department of Surgery, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrose","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun R.","family":"Flerchinger","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Barton","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"StatPearls","author":"Rajaretnam N","year":"2024","unstructured":"Rajaretnam N, Lieske B. Ileostomy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519003\/"},{"key":"e_1_3_4_3_2","first-page":"145749692412284","article-title":"A retrospective cohort study on renal morbidity related to stoma type in inflammatory bowel disease patients following colectomy and ileal pouch-anal anastomosis surgery","volume":"1","author":"Lundstr\u00f6m S","year":"2024","unstructured":"Lundstr\u00f6m S, Buchwald P, Agger E. A retrospective cohort study on renal morbidity related to stoma type in inflammatory bowel disease patients following colectomy and ileal pouch-anal anastomosis surgery. Scand J Surg. 2024;1:14574969241228411.","journal-title":"Scand J Surg"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-010-1086-3"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-012-2073-5"},{"key":"e_1_3_4_6_2","first-page":"1","article-title":"Postoperative outcomes and identification of risk factors for complications after emergency intestinal stoma surgery - a multicentre retrospective study","volume":"1","author":"MacDonald S","year":"2024","unstructured":"MacDonald S, Wong LS, Ng HJ, et al. Postoperative outcomes and identification of risk factors for complications after emergency intestinal stoma surgery - a multicentre retrospective study. Colorectal Dis. 2024;1:1.","journal-title":"Colorectal Dis"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-022-02580-6"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"issue":"8875","key":"e_1_3_4_9_2","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","unstructured":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821\u2013828.","journal-title":"Lancet"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-017-2961-y"},{"issue":"5","key":"e_1_3_4_12_2","first-page":"369","article-title":"Changes in glucocorticoid and mineralocorticoid hormone levels due to compensation for ileostomy losses","volume":"2","author":"Huber FX","year":"2001","unstructured":"Huber FX, Lucas M, Stern J, et al. Changes in glucocorticoid and mineralocorticoid hormone levels due to compensation for ileostomy losses. Int J Surg Investig. 2001;2(5):369-375.","journal-title":"Int J Surg Investig"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrae051"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e31823d0ec5"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.24.8.702"},{"issue":"2","key":"e_1_3_4_16_2","first-page":"218","article-title":"Ileostomy diarrhea: pathophysiology and management","volume":"33","author":"Rowe KM","year":"2020","unstructured":"Rowe KM, Schiller LR. Ileostomy diarrhea: pathophysiology and management. Proc (Bayl Univ Med Cent). 2020;33(2):218-226.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_4_19_2","unstructured":"National Cancer Institute. NCI Comorbidity Index Overview [Internet]. Bethesda MD: National Cancer Institute; [updated 2024 April 19; cited 2024 Dec 6]. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0003134820971574"}],"container-title":["The American Surgeon\u2122"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00031348241307396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00031348241307396","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00031348241307396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:37:08Z","timestamp":1777379828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00031348241307396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/00031348241307396"],"URL":"https:\/\/doi.org\/10.1177\/00031348241307396","relation":{},"ISSN":["0003-1348","1555-9823"],"issn-type":[{"value":"0003-1348","type":"print"},{"value":"1555-9823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}